Regulatory causality evaluation methods applied in kava hepatotoxicity: Are they appropriate?

Regulatory Toxicology and Pharmacology

Volumn 59, Issue 1, 2011, Pages 1-7

  Teschke, Rolf ^a   Wolff, Albrecht ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Causality assessment; Drug induced liver injury; Hepatotoxicity; Herbal hepatotoxicity; Herbs induced liver injury; Kava; Kava hepatotoxicity; Toxic liver disease; Toxic liver injury

Indexed keywords

KAVA;

ACCIDENT; DATA MINING; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MONITORING; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; LATENT PERIOD; LIVER TOXICITY; NOTE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RATING SCALE; RISK ASSESSMENT; SIGNAL TRANSDUCTION;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-ANXIETY AGENTS; CAUSALITY; DRUG AND NARCOTIC CONTROL; DRUG-INDUCED LIVER INJURY; HUMANS; KAVA; PLANT EXTRACTS; RISK ASSESSMENT; RISK FACTORS; WORLD HEALTH ORGANIZATION;

PIPER METHYSTICUM;

EID: 78751566523     PISSN: 02732300     EISSN: 10960295     Source Type: Journal    
DOI: 10.1016/j.yrtph.2010.09.006     Document Type: Note

References (48)

1. Aithal G.P., Rawlins M.D., Day C.P. Accuracy of hepatic adverse drug reactions reported in one English health region. Brit. Med. J. 1999, 319:1541.
2. Aithal G.P., Rawlins M.D., Day C.P. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions. J. Hepatol. 2000, 33:949-952.
3. Andrade R.J., Camargo R., Lucena M.I., González-Grande R. Causality assessment in drug-induced hepatotoxicity. Expert Opin. Drug Saf. 2004, 3:329-344.
4. Andrade R.J., Guilarte J., Salmerón F.J., Lucena M.I., Bellot V. Benzylpenicillin-induced prolonged cholestasis. Ann. Pharmacother. 2001, 35:783-784.
5. Andrade R.J., Lucena M.I., Fernández M.C., Pelaez G., Pachkoria K., García-Ruiz E., García-Muñoz B., Gonzalez-Grande R., Pizarro A., Durán J.A., Jiménez M., Rodrigo L., Romero-Gomez M., Navarro J.M., Planas R., Costa J., Borras A., Soler A., Salmerón J., Martin-Vivaldi R. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005, 129:512-521. Spanish Group for the Study of Drug-induced Liver Disease.
6. Andrade R.J., Lucena M.I., Kaplowitz N., García-Muñoz B., Borraz Y., Pachkoria K., García-Cortés M., Fernández M.C., Pelaez G., Rodrigo L., Durán J.A., Costa J., Planas R., Barriocanal A., Guaner C., Romero-Gomez M., Muņoz-Yagüe T., Salmerón J., Hidalgo R. Outcome of acute idiosyncratic drug-induced liver injury: long term follow-up in a hepatotoxicity registry. Hepatology 2006, 44:1581-1588.
7. Bénichou C., Danan G., Flahault A. Causality assessment of adverse reactions to drugs - II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J. Clin. Epidemiol. 1993, 46:1331-1336.
8. BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn. Federal Institute for Drugs and Medicinal Products in Germany), 2002. Rejection of Drug Risks, Step II. As Related to: Kava-Kava (Piper methysticum)-containing, and Kavain-containing Drugs, Including Homeopathic Preparations with a Final Concentration up to, and Including D4, June 14, 2002. (accessed 20.07.10). http://www.spc.int/cis/documents/02_0714_BfArM_Kava_Removal.pdf.
9. BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Bonn. Federal Institute for Drugs and Medicinal Products in Germany), 2005. Kava-Kava, May 12, 2005. (accessed 20.07.10). http://www.bfarm.de/DE/Pharmakovigilanz/risikoinfo/functions/2005/risikoinfo-2005-node.html.
10. Borrelli F., Ernst E. Black cohosh (Cimicifuga racemosa): a systematic review of adverse events. Am. J. Obstet. Gynecol. 2008, 199:455-466.
11. Danan G., Bénichou C. Causality assessment of adverse reactions to drugs - I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J. Clin. Epidemiol. 1993, 46:1323-1330.
12. Denham A., McIntyre M., Whitehouse J. Kava - the unfolding story: report on a work-in-progress. J. Altern. Complement. Med. 2002, 8:237-263.
13. García-Cortés M., Lucena M.I., Andrade R.J., Romero-Gomez M., Fernández M.C. Lansoprazole-induced hepatic dysfunction. Ann. Pharmacother. 2003, 37:1731.
14. García-Cortés M., Lucena M.I., Andrade R.J., Camargo R., Alcántara R. Is the Naranjo probability scale accurate enough to ascertain causality in drug-induced hepatotoxicity?. Ann. Pharmacother. 2004, 38:1540-1541.
15. García-Cortés M., Lucena M.I., Pachkoria K., Borraz Y., Hidalgo R., Andrade R.J. Evaluation of Naranjo Adverse Drug Reactions Probability Scale in causality assessment of drug-induced liver injury. Aliment. Pharmacol. Ther. 2008, 27:780-789.
16. Gunawan B., Kaplowitz N. Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab. Rev. 2004, 36:301-312.
17. Health Canada, 2010. Black cohosh products and liver toxicity: update. Canadian Adverse React. Newslett. 20, 1-3. (accessed 20.07.10). http://www.hc-sc.gc.ca/dhp-mps/medeff/bulletin/carn-bcei_v20n1-eng.php#a1t1.
18. Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001, 33:308-310.
19. Lanctot K.L., Naranjo C.A. Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. Clin. Pharmacol. Ther. 1995, 58:692-698.
20. Lee W.M. Assessing causality in drug-induced liver injury. J. Hepatol. 2000, 33:1003-1005.
21. Lee W.M. Drug-induced hepatotoxicity. New Engl. J. Med. 2003, 349:474-485.
22. Liss G., Lewis J.H. Drug-induced liver injury: what was new in 2008?. Expert Opin. Drug Metab. Toxicol. 2009, 5:843-860.
23. Lucena M.I., Camargo R., Andrade R.J., Perez-Sanchez C.J., Cuesta F.S.D.L. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 2001, 33:23-30.
24. Macedo A.F., Marques F.B., Ribeiro C.F., Teixeira F. Causality assessment of adverse drug reactions: comparison of the results obtained from published decisional algorithms and from the evaluations of an expert panel, according to different levels of imputability. J. Clin. Pharm. Ther. 2003, 28:137-143.
25. Maddrey W.C. Drug-induced hepatotoxicity 2005. J. Clin. Gastroenterol. 2005, 39:S83-S89.
26. Maria V.A., Victorino R.M. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997, 26:664-669.
27. Naranjo C.A., Busto U., Abel J.G., Sellers E.M. Empiric delineation of the probability spectrum of adverse drug reactions. Clin. Pharmacol. Ther. 1981, 29:267-268.
28. Naranjo C.A., Busto U., Sellers E.M., Sandor P., Ruiz I., Roberts E.A., Janecek E., Domecq C., Greenblatt D.J. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 1981, 30:239-245.
29. Navarro V.J. Herbal and dietary supplement hepatotoxicity. Semin. Liver Dis. 2009, 29:373-382.
30. Rochon J., Protiva P., Seeff L.B., Fontana R.J., Liangpunsakul S., Watkins P.B., Davern T., McHutchison J.G. For the Drug-Induced Liver Injury Network (DILIN). Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 2008, 48:1175-1183.
31. Rockey D.C., Seeff L.B., Rochon J., Freston J., Chalasani N., Bonachini M., Fontana R.J., Hayashi P.H. For the US Drug-induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel Uclaf Causality Assessment Method. Hepatology 2010, 51:2117-2126.
32. Schmidt M., Morgan M., Bone K., McMillan J. Kava: a risk-benefit assessment. The Essential Guide to Herbal Safety 2005, 155-221. Elsevier Churchill Livingstone, St. Louis (Missouri). M. Mills, K. Bone (Eds.).
33. Schulze J., Raasch W., Siegers C.P. Toxicity of kava pyrones, drug safety and precautions - a case study. Phytomedicine 2003, 10(Suppl. IV):68-73.
34. Seeff K.B. Herbal hepatotoxicity. Clin. Liver Dis. 2007, 11:577-596.
35. Teschke R. Kava hepatotoxicity: a clinical review. Ann. Hepatol. 2010, 9:251-265.
36. Teschke R. Kava hepatotoxicity: pathogenetic aspects and prospective considerations. Liver Int. 2010, 30:1270-1278.
37. Teschke R., Bahre R. Severe hepatotoxicity by Indian Ayurvedic herbal products: a structured causality assessment. Ann. Hepatol. 2009, 8:258-266.
38. Teschke R., Bahre R., Fuchs J., Wolff A. Black cohosh hepatotoxicity: quantitative causality evaluation in nine suspected cases. Menopause 2009, 16:956-965.
39. Teschke R., Bahre R., Genthner A., Fuchs J., Schmidt-Taenzer W., Wolff A. Suspected black cohosh hepatotoxicity - challenges and pitfalls of causality assessment. Maturitas 2009, 63:302-314.
40. Teschke R., Bahre R., Genthner A., Fuchs J., Schmidt-Taenzer W., Wolf A. Suspected black cohosh hepatotoxicity - causality assessment versus safety signal. Quality versuch quantity. Maturitas 2009, 64:141-142.
41. Teschke, R., Fuchs, J., Bahre, R., Genthner, A., Wolff, A., 2010. Kava hepatotoxicity: comparative study of two structured quantitative methods for causality assessment. J. Clin. Pharm. Ther. 34. doi:10.1111/j.1365-2710.2009.01131.x.
42. Teschke R., Gaus W., Loew D. Kava extracts: safety and risks including rare hepatotoxicity. Phytomedicine 2003, 10:440-446.
43. Teschke R., Schwarzenboeck A., Hennermann K.H. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur. J. Gastroenterol. Hepatol. 2008, 20:1182-1193.
44. Teschke R., Schwarzenboeck A., Hennermann K.H. Causality assessment in hepatotoxicity by drugs and dietary supplements. Brit. J. Clin. Pharmacol. 2008, 66:758-766.
45. Teschke R., Wolff A. Kava hepatotoxicity: regulatory data selection and causality assessment. Dig. Liver Dis. 2009, 41:891-901.
46. WHO, 2000. Causality Assessment of Suspected Adverse Reactions. WHO Collaboratoring Centre for International Drug Monitoring (Uppsala Monitoring Centre, UMC). Database, 2000. (accessed 20.07.10). http://www.who-umc.org/DynPage.aspx?id=22682.
47. WHO (World Health Organization), 2007. Assessments of the Risk of Hepatotoxicity with Kava Products. WHO Document Production Services, Geneva, Switzerland.
48. Zimmerman H.J. Hepatotoxicity 1999, Lippincott Williams & Wilkins, Philadelphia.